ImmunoGen Announces Departure of Sandra Poole
January 23 2017 - 4:01PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Sandra Poole, Executive Vice President,
Technical Operations and Commercial Development, will leave the
Company at the end of January to pursue other opportunities. Thomas
Ryll, Ph.D., Vice President, Technical Operations, will assume
responsibility for the Company’s manufacturing and supply chain
operations, reporting directly to Mark Enyedy, President and Chief
Executive Officer of ImmunoGen.
“I thank Sandra for the significant contributions she has made
to ImmunoGen since joining the Company in 2014,” said Mr. Enyedy.
“Sandra built a talented Technical Operations organization, and a
strong network of manufacturing partners ensuring the reliable
supply of high-quality products and CMC readiness to support our
development and collaborator programs. We wish Sandra the very best
and look forward to Thomas taking on a broader leadership role as
ImmunoGen evolves into a fully-integrated oncology company.”
Dr. Ryll joined ImmunoGen in 2015 and previously oversaw
ImmunoGen’s manufacturing facility, Process and Analytical
Development, external manufacturing, and Environmental Health and
Safety functions. He has more than 20 years of experience in
biologics operations and technology development, spanning all
aspects of mammalian cell culture biomanufacturing. Dr. Ryll
previously held positions of increasing responsibility at
Genentech, Abgenix, Tanox and, most recently, nine years with
Biogen.
“I greatly appreciate the opportunity I've had to work with such
a talented team of professionals, committed to delivering
innovative therapies to patients with cancer. ImmunoGen is at an
exciting point in its evolution and I’m confident the Company will
continue to be a leader in ADCs,” said Ms. Poole.
About ImmunoGen, Inc.ImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics
using its proprietary ADC technology. ImmunoGen’s lead product
candidate, mirvetuximab soravtansine, is in a Phase 3 trial for
FRα-positive platinum-resistant ovarian cancer, and is in Phase
1b/2 testing in combination regimens for earlier-stage disease.
ImmunoGen’s ADC technology is used in Roche’s marketed product,
Kadcyla®, in three other clinical-stage ImmunoGen product
candidates, and in programs in development by partners Amgen,
Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a
member of the Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170123006039/en/
Investor Contact:ImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorMedia
Contacts:ImmunoGen, Inc.Amy Reilly,
781-895-0138amy.reilly@immunogen.comorFTI Consulting Inc.Robert
Stanislaro, 212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024